ClinicalTrials.gg
Active, not recruitingNCT05996003Updated Sep 15, 2026

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

A Phase 2 interventional study of NS-089/NCNP-02 in Duchenne Muscular Dystrophy, Exon 44 and DMD, sponsored by NS Pharma, Inc.. Active, not recruiting at 29 sites in 7 countries. Open to male participants aged 4 Years to 14 Years. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by NS Pharma, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
4 Years to 14 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc. — 1 open to participants now, 5 under way, 1 of them phase 3. Muscular Dystrophy, Duchenne · NS Pharma, Inc..

Started
2024
with 1 other
Phase 2
5 of 10
1 open now
Registered
8th of 10
by date

Among the 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc., this one is one of 2 that started in 2024, is one of 5 in phase 2, and was the 8th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

1 of the 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc. is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 4 Years to 14 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Muscular Dystrophy, Duchenne by NS Pharma, Inc., or all of them as a file.
02

Study summary

This is a Phase 2, open-label, multi-center, 2-part study of NS-089/NCNP-02 administered by weekly IV infusion to ambulant boys aged ≥4 to \<15 years with DMD due to mutations amenable to exon 44 skipping. Participants will receive a selected dose of NS-089/NCNP-02 administered once weekly.

The study consists of 2 parts: Part 1 and Part 2. Six participants (Cohort 1) will participate in both Part 1 and Part 2, and 14 participants (Cohort 2) will be added for Part 2.

03

Conditions studied

  • Duchenne Muscular Dystrophy
  • Exon 44
  • DMD

Keywords

  • Exon 44 Skipping
  • DMD
  • Brogidirsen
04

Who can participate

Ages eligible
4 Years to 14 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male ≥ 4 years and \<15 years of age
  • Confirmed DMD mutation(s) in the dystrophin gene that is amenable to skipping of exon 44 to restore the dystrophin mRNA reading frame
  • Able to walk independently without assistive devices
  • Ability to complete the TTSTAND without assistance in \<20 seconds
  • Stable dose of for at least 3 months and the dose is expected to remain on a stable dose for the duration of the study.
  • Other inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  • Has a body weight of \<20 kg at the time of (applies to participants screening for Part 1 only)
  • Evidence of symptomatic cardiomyopathy
  • Current or previous treatment with anabolic steroids (e.g., oxandrolone) or products containing resveratrol or adenosine triphosphate within 3 months prior to first dose of study drug
  • Current or previous treatment with any other drug within 3 months prior to the first dose of study drug or within 5 times the half-life of a medication, whichever is longer
  • Surgery within the 3 months prior to the first dose of study drug or planned during the study duration
  • Previously treated in an interventional study of NS-089/NCNP-02
  • Having received exon skipping oligonucleotide within 1 year prior to the first dose of IP
  • Other exclusion criteria may apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    NS-089/NCNP-02

    Experimental: NS-089/NCNP-02 NS-089/NCNP-02 solution for infusion (Cohort 1) NS-089/NCNP-02 solution for infusion (Cohort 2)

    Drug: NS-089/NCNP-02

Interventions

  • DrugNS-089/NCNP-02

    Drug page: BrogidirsenStudies of BrogidirsenBrogidirsen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cohort 1: Part 1 Dose Level 1-3: a 4-week Treatment Phase at each treatment dose level Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1 Cohort 2: Part 2 Single Dose Level: a 24-week Treatment Phase at the MTD of Part 1

    Also known as: Brogidirsen

06

What researchers measure

Primary outcomes

  1. Adverse Event and Adverse Drug Reaction

    Time frame: through study completion, up to follow-up phone call for Part 2

  2. Plasma pharmacokinetic (PK) parameters

    Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Maximum plasma concentration (Cmax) of NS-089/NCNP-02

  3. Plasma pharmacokinetic (PK) parameters

    Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Time of the maximum plasma concentration (Tmax) of NS-089/NCNP-02

  4. Plasma pharmacokinetic (PK) parameters

    Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Terminal half-life (T1/2) of NS-089/NCNP-02

  5. Plasma pharmacokinetic (PK) parameters

    Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Area under the concentration-time curve from time 0 to the last time point (AUC0-t) of NS-089/NCNP-02

  6. Plasma pharmacokinetic (PK) parameters

    Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Area under the concentration-time curve from time 0 to infinity (AUC0-∞) of NS-089/NCNP-02

  7. Plasma pharmacokinetic (PK) parameters

    Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Total body clearance (CLtot) of NS-089/NCNP-02

  8. Plasma pharmacokinetic (PK) parameters

    Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] The volume in the terminal state (Vz) of NS-089/NCNP-02

  9. Urine pharmacokinetic parameters

    Time frame: Day1, Week4 for each dose for Part 1, Day1 and Week24 for Part 2] Urinary excretion of NS-089/NCNP-02

  10. Change from baseline in skeletal muscle dystrophin protein by immunoblot (Western blot).

    Time frame: Baseline, Week25

Secondary outcomes

  1. Change from baseline in skeletal muscle dystrophin protein by mass spectrometry.

    Time frame: Baseline, Week25

  2. Change from baseline in skeletal muscle dystrophin protein levels by immunofluorescence staining.

    Time frame: Baseline, Week25

  3. Change from baseline in percentage of exon 44-skipped mRNA of skeletal muscle dystrophin

    Time frame: Baseline, Week25

  4. North Star Ambulatory Assessment (NSAA) score

    The NSAA is a functional scale devised for use in ambulant children with Duchenne muscular dystrophy (DMD). It consists of 17 activities graded 0 (unable to perform), 1 (performs with modifications), 2 (normal movement). It assesses abilities necessary to remain ambulant that have been found to progressively deteriorate in untreated DMD patients, as well as in other muscular dystrophies such as Becker Muscular Dystrophy. NSAA Total Score ranges from 0 to 34, with a score of 34 implying normal function.

    Time frame: Baseline, Week13, Week25

  5. Time to Run/Walk 10 Meters (TTRW)

    Time frame: Baseline, Week13, Week25

  6. Time to Stand (TTSTAND)

    Time frame: Baseline, Week13, Week25

  7. Total distance of 6 Minute Walk Test (6MWT)

    Time frame: Baseline, Week13, Week25

  8. Time to Climb 4 Stairs (TTCLIMB)

    Time frame: Baseline, Week13, Week25

  9. Muscle strength measured by Quantitative Muscle Testing (QMT)

    Time frame: Baseline, Week13, Week25

  10. Grip and pinch strength

    Time frame: Baseline, Week13, Week25

  11. Performance of Upper Limb (PUL) 2.0. score

    The PUL 2.0 provides both a total score and sub-scores for the 3 domains (shoulder, middle, and distal) that in DMD are progressively involved with a proximal to distal gradient. The PUL includes 22 items with an entry item to define the starting functional level. The 22 items are subdivided into the high-level shoulder dimension (6 items), middle level elbow dimension (9 items), and distal wrist and hand dimension (7 items). For weaker patients, a low score on the entry item (0-2) means high level items do not need to be performed. Scoring options vary across the scale between 0-1 and 0-2 according to performance. Each dimension can be scored separately with a maximum score of 12 for the high-level shoulder dimension, 17 for the middle level elbow dimension, and 13 for the distal wrist and hand dimension. A total score can be achieved by adding the 3 level scores (maximum total score of 42).

    Time frame: Baseline, Week13, Week25

07

Study locations

29 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 36 months after the start.

Of 40 industry-sponsored phase 2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's planned 36 months is above that.

Counting every sponsor, half of 47 studies reached it within 31 months; a quarter within 20 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2023
First posted
Aug 16, 2023
StartActual
Feb 22, 2024
Primary completionEst.
Feb 26, 2027
CompletionEst.
Feb 26, 2027
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05996003
Lead sponsor
NS Pharma, Inc.
Collaborators
Nippon Shinyaku Co., Ltd.
Responsible party
Sponsor
First posted
Aug 16, 2023
Start date
Feb 22, 2024
Primary completion
Feb 26, 2027 (estimated)
Completion
Feb 26, 2027 (estimated)
Last update
Sep 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brogidirsen

Start the discussion